Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force.
about
Risk-reducing medication for primary breast cancer: a network meta-analysisHereditary Cancer: Example of a Public Health Approach to Ensure Population Health Benefits of Genetic MedicineMolecular cancer prevention: Current status and future directionsEpidemiology and management of osteoporosis in the People's Republic of China: current perspectivesPreventive treatments for breast cancer: recent developmentsMedical prevention of breast cancerBreast Cancer Chemoprevention: A Network Meta-Analysis of Randomized Controlled TrialsBreast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial.Actualizing Personalized Healthcare for Women through Connected Data Systems: Breast Cancer Screening and Diagnosis.How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention?Insulin-like growth factor-I inhibition with pasireotide decreases cell proliferation and increases apoptosis in pre-malignant lesions of the breast: a phase 1 proof of principle trial.Primary chemoprevention of breast cancer: Are the adverse effects too burdensome?An Effective Multimodal Curriculum to Teach Internal Medicine Residents Evidence-Based Breast Health.Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ.Acceptance and adherence to chemoprevention among women at increased risk of breast cancerContribution of extended family history in assessment of risk for breast and colon cancer.Pleomorphic Lobular Carcinoma In Situ: Radiologic-Pathologic Features and Clinical Management.Barriers and Facilitators to Patient-Provider Communication When Discussing Breast Cancer Risk to Aid in the Development of Decision Support Tools.Pomegranate exerts chemoprevention of experimentally induced mammary tumorigenesis by suppression of cell proliferation and induction of apoptosis.Affective forecasting and medication decision making in breast-cancer preventionThe Activities and Impact of State Programs to Address Hereditary Breast and Ovarian Cancer, 2011-2014.Development of a personalized decision aid for breast cancer risk reduction and management.Tamoxifen synergizes with 4-(E)-{(4-hydroxyphenylimino)-methylbenzene, 1,2-diol} and 4-(E)-{(p-tolylimino)-methylbenzene-1,2-diol}, novel azaresveratrol analogs, in inhibiting the proliferation of breast cancer cells.Measuring selective estrogen receptor modulator (SERM)-membrane interactions with second harmonic generationSkeletal manifestations of treatment of breast cancer on premenopausal women.Breast cancer prevention with anti-estrogens: review of the current evidence and future directions.Chemoprevention Uptake among Women with Atypical Hyperplasia and Lobular and Ductal Carcinoma In Situ.Population-Attributable Risk Proportion of Clinical Risk Factors for Breast Cancer.The relationship between risk factors and medication adherence among breast cancer survivors: What explanatory role might depression play?Joint relative risks for estrogen receptor-positive breast cancer from a clinical model, polygenic risk score, and sex hormones.Accounting for individualized competing mortality risks in estimating postmenopausal breast cancer risk.The Japanese Breast Cancer Society clinical practice guidelines for epidemiology and prevention of breast cancer, 2015 edition.Introducing a Comprehensive Informatics Framework to Promote Breast Cancer Risk Assessment and Chemoprevention in the Primary Care Setting.Genetic and environmental factors and serum hormones, and risk of estrogen receptor-positive breast cancer in pre- and postmenopausal Japanese women.Breast cancer prevention for BRCA1 and BRCA2 mutation carriers: is there a role for tamoxifen?Factors Associated with Interest in Gene-Panel Testing and Risk Communication Preferences in Women from BRCA1/2 Negative Families.The impact of patient age on breast cancer risk prediction models.Economic evaluation of using a genetic test to direct breast cancer chemoprevention in white women with a previous breast biopsy.Antiplatelet Therapy in Breast Cancer Patients Using Hormonal Therapy: Myths, Evidence and Potentialities - Systematic ReviewInterdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, AWMF Registry Nummer 032/034-OL, April 2018) - Part 1 with Recommendations on the Epidemiology, Screening, Diagnosis and Hereditary Factors o
P2860
Q24185817-70F8B230-A10D-4F7F-BB40-DC13ECF549F9Q26740273-AA412E46-2A4D-45F2-92A6-6814E330A621Q26797207-891CC429-E693-4F6D-AB5A-2479583E51A0Q27005978-652CF3E8-F105-4A98-94F4-9C52B4531F1FQ27025375-D85BEBAD-6428-40FE-B8B3-1839B559AD59Q28086915-8A256D5F-54ED-4694-AC39-6629553B0229Q28269986-C0D2DB3B-2C4E-4E0F-BA51-6905C1A838CBQ30238753-EFE5E7AD-4DB6-430E-98EB-9EEED03AD2E4Q30731867-F180ED6B-670C-4FC9-976A-697AAA5BF66BQ33767120-BE17D8CC-C520-4F29-9DF6-9BA8821C14BEQ35000609-D4AED9C7-32C4-4D74-AAFF-C0726E5C1230Q35744037-E0BA6FAD-C9DB-492C-8BE9-C6D8D844C760Q35770373-EF7546C2-6BDC-4E60-B6AF-DADF6253C4ADQ35812120-D485041E-917F-4DA8-AF55-3B4F6278099CQ35854935-42BF8A15-BA5B-478F-922C-1F81E0B6C49EQ36118708-D9DB00CF-8A60-4A6B-A6CA-E92B4EFAFAA1Q36172503-89F1CAA7-8E23-4D51-AD24-C6648DC19742Q36613582-3BC775AE-722C-479E-A0A0-0CE92BD3C80CQ36668547-6C2B58C5-DD4D-4EF4-8C3B-BABDD921834CQ36905513-12390273-D50E-4F76-9A32-D68CE090E368Q37069558-61125146-AB30-4CDF-92A5-8F6879C1538EQ37506839-E4A7E669-354F-4E20-B192-398E347C140CQ37588360-9D68A185-8526-4E79-8F03-DF7184661E8EQ37731586-07A1B5B0-1D94-4593-B4E5-8AED6F967904Q38152661-4D66BC7F-7518-4395-91E1-E51A3D0525F5Q38599973-55AF977C-976C-4B81-90EF-C8A080500FBEQ38727084-FA88C08B-6F2D-4C48-93FD-9A989DE23914Q38984143-AEFC99FB-B070-4226-8D50-282A800ED3FCQ39053716-D2791804-B7C7-4D48-B551-5764C61262F9Q40089754-570B1324-87DC-4176-99A1-62501813EFC8Q40498027-0CF42ED3-8D50-47DA-A58B-998A26906C51Q40912150-A10F86D5-16FB-43FB-840D-08F763604F9EQ41246404-EA15A913-ED8D-4055-862B-4E63394B69C3Q42371580-226237AC-09FC-41EB-BF8B-55C28B590951Q43624639-13BDBB53-D0C5-47A8-8CBC-E26C4BBB133AQ48029327-DF50AB3D-AE59-4520-A4A8-0B86CFC45464Q48280660-16E56D38-E4F2-4987-BF2A-985AE94A3D01Q50460101-1061BB5F-005B-469F-9DD6-6B0298101084Q57108351-6580C26A-3DCA-48D8-9F37-7DDD5FEF347EQ58592781-7E9BAB41-C801-4E28-8FC6-F354F0EAFF46
P2860
Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force.
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Use of medications to reduce r ...... reventive Services Task Force.
@ast
Use of medications to reduce r ...... reventive Services Task Force.
@en
Use of medications to reduce r ...... reventive Services Task Force.
@nl
type
label
Use of medications to reduce r ...... reventive Services Task Force.
@ast
Use of medications to reduce r ...... reventive Services Task Force.
@en
Use of medications to reduce r ...... reventive Services Task Force.
@nl
prefLabel
Use of medications to reduce r ...... reventive Services Task Force.
@ast
Use of medications to reduce r ...... reventive Services Task Force.
@en
Use of medications to reduce r ...... reventive Services Task Force.
@nl
P2093
P1476
Use of medications to reduce r ...... reventive Services Task Force.
@en
P2093
Heidi D Nelson
Jessica C Griffin
M E Beth Smith
Rongwei Fu
P304
P356
10.7326/0003-4819-158-8-201304160-00005
P407
P577
2013-04-01T00:00:00Z